Gene expression profiles from hypertrophic scar fibroblasts before and after IL-6 stimulation

Mohan R K Dasu, Hal K. Hawkins, Robert E. Barrow, Hui Xue, David Herndon

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The structural rearrangement of collagen fibres in hypertrophic scar causes abnormal contracture, low tensile strength, and raised scars, which cause functional impairment and disfigurement. It is hypothesized that changes in the genes of cytokines, extracellular matrix proteins, and proteins regulating programmed cell death are related to hypertrophic scar formation. To test this hypothesis, fibroblasts were cultured from hypertrophic scars and their response to interleukin-6 (IL-6) stimulation was studied by defining their gene expression profiles. Affymetrix gene chip analysis was used to identify up- or down-regulation in the 12 625 genes present in the affymetrix array. RT-PCR and ELISA assays were used to validate microarray expression profiles further. Comparison of gene profiles showed an increase of 12 genes in hypertrophic scar fibroblasts compared with normal skin fibroblasts, while the expression of 14 genes decreased. Thirty-three genes were affected by IL-6 treatment in the hypertrophic scar fibroblasts, while 57 genes were affected in normal skin fibroblasts. Messenger RNA to β-actin ratios for matrix metalloproteinase-1 (MMP-1) and MMP-3 were increased with IL-6 in normal skin fibroblasts from 2.43 ± 0.06 to 5.50 ± 0.45 and from 0.75 ± 0.09 to 1.98 ± 0.01, respectively. No change in these matrix metalloproteinases could be shown with IL-6 stimulation in hypertrophic scar fibroblasts. Secreted protein levels of pro-MMP-1 and MMP-3 were elevated in the supernatants from normal skin fibroblasts from 2.00 ± 0.09 and 1.72 ± 0.10 ng/ml to 4.60 ± 0.12 and 3.41 ± 0.20 ng/ml, respectively, after treatment with IL-6 (p < 0.05). No changes were observed in hypertrophic scar fibroblasts treated with IL-6. Values are means ± SEM. The absence of any up-regulation of MMP-1 and MMP-3 in hypertrophic scar fibroblasts, in response to IL-6, suggests that suppression of matrix metalloproteinases may play a role in the excessive accumulation of collagen formed in hypertrophic scars. While the pathogenesis of abnormal hypertrophic scars remains poorly understood, the use of gene expression arrays may prove helpful in identifying the mechanisms responsible for this type of abnormal scar formation and in formulating an effective therapeutic protocol.

Original languageEnglish (US)
Pages (from-to)476-485
Number of pages10
JournalJournal of Pathology
Volume202
Issue number4
DOIs
StatePublished - Apr 2004

Fingerprint

Hypertrophic Cicatrix
Transcriptome
Interleukin-6
Fibroblasts
Matrix Metalloproteinases
Matrix Metalloproteinase 1
Genes
Skin
Cicatrix
Up-Regulation
Collagen
Gene Expression
Apoptosis Regulatory Proteins
Tensile Strength
Extracellular Matrix Proteins
Contracture
Oligonucleotide Array Sequence Analysis
Actins
Therapeutics
Down-Regulation

Keywords

  • Fibroblasts
  • Gene profiles
  • Hypertrophic scar
  • IL-6
  • Matrix metalloproteinases

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Dasu, M. R. K., Hawkins, H. K., Barrow, R. E., Xue, H., & Herndon, D. (2004). Gene expression profiles from hypertrophic scar fibroblasts before and after IL-6 stimulation. Journal of Pathology, 202(4), 476-485. https://doi.org/10.1002/path.1539

Gene expression profiles from hypertrophic scar fibroblasts before and after IL-6 stimulation. / Dasu, Mohan R K; Hawkins, Hal K.; Barrow, Robert E.; Xue, Hui; Herndon, David.

In: Journal of Pathology, Vol. 202, No. 4, 04.2004, p. 476-485.

Research output: Contribution to journalArticle

Dasu, MRK, Hawkins, HK, Barrow, RE, Xue, H & Herndon, D 2004, 'Gene expression profiles from hypertrophic scar fibroblasts before and after IL-6 stimulation', Journal of Pathology, vol. 202, no. 4, pp. 476-485. https://doi.org/10.1002/path.1539
Dasu, Mohan R K ; Hawkins, Hal K. ; Barrow, Robert E. ; Xue, Hui ; Herndon, David. / Gene expression profiles from hypertrophic scar fibroblasts before and after IL-6 stimulation. In: Journal of Pathology. 2004 ; Vol. 202, No. 4. pp. 476-485.
@article{2f3b9fae10b64985841ca10e27839932,
title = "Gene expression profiles from hypertrophic scar fibroblasts before and after IL-6 stimulation",
abstract = "The structural rearrangement of collagen fibres in hypertrophic scar causes abnormal contracture, low tensile strength, and raised scars, which cause functional impairment and disfigurement. It is hypothesized that changes in the genes of cytokines, extracellular matrix proteins, and proteins regulating programmed cell death are related to hypertrophic scar formation. To test this hypothesis, fibroblasts were cultured from hypertrophic scars and their response to interleukin-6 (IL-6) stimulation was studied by defining their gene expression profiles. Affymetrix gene chip analysis was used to identify up- or down-regulation in the 12 625 genes present in the affymetrix array. RT-PCR and ELISA assays were used to validate microarray expression profiles further. Comparison of gene profiles showed an increase of 12 genes in hypertrophic scar fibroblasts compared with normal skin fibroblasts, while the expression of 14 genes decreased. Thirty-three genes were affected by IL-6 treatment in the hypertrophic scar fibroblasts, while 57 genes were affected in normal skin fibroblasts. Messenger RNA to β-actin ratios for matrix metalloproteinase-1 (MMP-1) and MMP-3 were increased with IL-6 in normal skin fibroblasts from 2.43 ± 0.06 to 5.50 ± 0.45 and from 0.75 ± 0.09 to 1.98 ± 0.01, respectively. No change in these matrix metalloproteinases could be shown with IL-6 stimulation in hypertrophic scar fibroblasts. Secreted protein levels of pro-MMP-1 and MMP-3 were elevated in the supernatants from normal skin fibroblasts from 2.00 ± 0.09 and 1.72 ± 0.10 ng/ml to 4.60 ± 0.12 and 3.41 ± 0.20 ng/ml, respectively, after treatment with IL-6 (p < 0.05). No changes were observed in hypertrophic scar fibroblasts treated with IL-6. Values are means ± SEM. The absence of any up-regulation of MMP-1 and MMP-3 in hypertrophic scar fibroblasts, in response to IL-6, suggests that suppression of matrix metalloproteinases may play a role in the excessive accumulation of collagen formed in hypertrophic scars. While the pathogenesis of abnormal hypertrophic scars remains poorly understood, the use of gene expression arrays may prove helpful in identifying the mechanisms responsible for this type of abnormal scar formation and in formulating an effective therapeutic protocol.",
keywords = "Fibroblasts, Gene profiles, Hypertrophic scar, IL-6, Matrix metalloproteinases",
author = "Dasu, {Mohan R K} and Hawkins, {Hal K.} and Barrow, {Robert E.} and Hui Xue and David Herndon",
year = "2004",
month = "4",
doi = "10.1002/path.1539",
language = "English (US)",
volume = "202",
pages = "476--485",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Gene expression profiles from hypertrophic scar fibroblasts before and after IL-6 stimulation

AU - Dasu, Mohan R K

AU - Hawkins, Hal K.

AU - Barrow, Robert E.

AU - Xue, Hui

AU - Herndon, David

PY - 2004/4

Y1 - 2004/4

N2 - The structural rearrangement of collagen fibres in hypertrophic scar causes abnormal contracture, low tensile strength, and raised scars, which cause functional impairment and disfigurement. It is hypothesized that changes in the genes of cytokines, extracellular matrix proteins, and proteins regulating programmed cell death are related to hypertrophic scar formation. To test this hypothesis, fibroblasts were cultured from hypertrophic scars and their response to interleukin-6 (IL-6) stimulation was studied by defining their gene expression profiles. Affymetrix gene chip analysis was used to identify up- or down-regulation in the 12 625 genes present in the affymetrix array. RT-PCR and ELISA assays were used to validate microarray expression profiles further. Comparison of gene profiles showed an increase of 12 genes in hypertrophic scar fibroblasts compared with normal skin fibroblasts, while the expression of 14 genes decreased. Thirty-three genes were affected by IL-6 treatment in the hypertrophic scar fibroblasts, while 57 genes were affected in normal skin fibroblasts. Messenger RNA to β-actin ratios for matrix metalloproteinase-1 (MMP-1) and MMP-3 were increased with IL-6 in normal skin fibroblasts from 2.43 ± 0.06 to 5.50 ± 0.45 and from 0.75 ± 0.09 to 1.98 ± 0.01, respectively. No change in these matrix metalloproteinases could be shown with IL-6 stimulation in hypertrophic scar fibroblasts. Secreted protein levels of pro-MMP-1 and MMP-3 were elevated in the supernatants from normal skin fibroblasts from 2.00 ± 0.09 and 1.72 ± 0.10 ng/ml to 4.60 ± 0.12 and 3.41 ± 0.20 ng/ml, respectively, after treatment with IL-6 (p < 0.05). No changes were observed in hypertrophic scar fibroblasts treated with IL-6. Values are means ± SEM. The absence of any up-regulation of MMP-1 and MMP-3 in hypertrophic scar fibroblasts, in response to IL-6, suggests that suppression of matrix metalloproteinases may play a role in the excessive accumulation of collagen formed in hypertrophic scars. While the pathogenesis of abnormal hypertrophic scars remains poorly understood, the use of gene expression arrays may prove helpful in identifying the mechanisms responsible for this type of abnormal scar formation and in formulating an effective therapeutic protocol.

AB - The structural rearrangement of collagen fibres in hypertrophic scar causes abnormal contracture, low tensile strength, and raised scars, which cause functional impairment and disfigurement. It is hypothesized that changes in the genes of cytokines, extracellular matrix proteins, and proteins regulating programmed cell death are related to hypertrophic scar formation. To test this hypothesis, fibroblasts were cultured from hypertrophic scars and their response to interleukin-6 (IL-6) stimulation was studied by defining their gene expression profiles. Affymetrix gene chip analysis was used to identify up- or down-regulation in the 12 625 genes present in the affymetrix array. RT-PCR and ELISA assays were used to validate microarray expression profiles further. Comparison of gene profiles showed an increase of 12 genes in hypertrophic scar fibroblasts compared with normal skin fibroblasts, while the expression of 14 genes decreased. Thirty-three genes were affected by IL-6 treatment in the hypertrophic scar fibroblasts, while 57 genes were affected in normal skin fibroblasts. Messenger RNA to β-actin ratios for matrix metalloproteinase-1 (MMP-1) and MMP-3 were increased with IL-6 in normal skin fibroblasts from 2.43 ± 0.06 to 5.50 ± 0.45 and from 0.75 ± 0.09 to 1.98 ± 0.01, respectively. No change in these matrix metalloproteinases could be shown with IL-6 stimulation in hypertrophic scar fibroblasts. Secreted protein levels of pro-MMP-1 and MMP-3 were elevated in the supernatants from normal skin fibroblasts from 2.00 ± 0.09 and 1.72 ± 0.10 ng/ml to 4.60 ± 0.12 and 3.41 ± 0.20 ng/ml, respectively, after treatment with IL-6 (p < 0.05). No changes were observed in hypertrophic scar fibroblasts treated with IL-6. Values are means ± SEM. The absence of any up-regulation of MMP-1 and MMP-3 in hypertrophic scar fibroblasts, in response to IL-6, suggests that suppression of matrix metalloproteinases may play a role in the excessive accumulation of collagen formed in hypertrophic scars. While the pathogenesis of abnormal hypertrophic scars remains poorly understood, the use of gene expression arrays may prove helpful in identifying the mechanisms responsible for this type of abnormal scar formation and in formulating an effective therapeutic protocol.

KW - Fibroblasts

KW - Gene profiles

KW - Hypertrophic scar

KW - IL-6

KW - Matrix metalloproteinases

UR - http://www.scopus.com/inward/record.url?scp=1842583836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842583836&partnerID=8YFLogxK

U2 - 10.1002/path.1539

DO - 10.1002/path.1539

M3 - Article

C2 - 15095275

AN - SCOPUS:1842583836

VL - 202

SP - 476

EP - 485

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 4

ER -